JP2022529651A - ペプチドに基づく非タンパク質カーゴ送達 - Google Patents

ペプチドに基づく非タンパク質カーゴ送達 Download PDF

Info

Publication number
JP2022529651A
JP2022529651A JP2021561766A JP2021561766A JP2022529651A JP 2022529651 A JP2022529651 A JP 2022529651A JP 2021561766 A JP2021561766 A JP 2021561766A JP 2021561766 A JP2021561766 A JP 2021561766A JP 2022529651 A JP2022529651 A JP 2022529651A
Authority
JP
Japan
Prior art keywords
shuttle agent
synthetic peptide
amino acids
peptide
cargo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021561766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529651A5 (https=
Inventor
ディヴィッド・グアイ
トマス・デルジュディス
ジャン－パスカル・レペティット－ストファエス
グザヴィエ・バーボー
ナンシー・メシエ
ステファニー・アレ
Original Assignee
フェルダン・バイオ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェルダン・バイオ・インコーポレーテッド filed Critical フェルダン・バイオ・インコーポレーテッド
Publication of JP2022529651A publication Critical patent/JP2022529651A/ja
Publication of JP2022529651A5 publication Critical patent/JP2022529651A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
JP2021561766A 2019-04-18 2020-04-17 ペプチドに基づく非タンパク質カーゴ送達 Pending JP2022529651A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA3040645A CA3040645A1 (en) 2019-04-18 2019-04-18 Peptide-based non-proteinaceous cargo delivery
CA3,040,645 2019-04-18
PCT/CA2020/050517 WO2020210916A1 (en) 2019-04-18 2020-04-17 Peptide-based non-proteinaceous cargo delivery

Publications (2)

Publication Number Publication Date
JP2022529651A true JP2022529651A (ja) 2022-06-23
JP2022529651A5 JP2022529651A5 (https=) 2023-07-04

Family

ID=72836884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021561766A Pending JP2022529651A (ja) 2019-04-18 2020-04-17 ペプチドに基づく非タンパク質カーゴ送達

Country Status (10)

Country Link
US (1) US12428447B2 (https=)
EP (1) EP3956348A4 (https=)
JP (1) JP2022529651A (https=)
KR (1) KR20220031545A (https=)
CN (2) CN114008210B (https=)
AU (1) AU2020260283A1 (https=)
CA (2) CA3040645A1 (https=)
IL (1) IL287271A (https=)
SG (1) SG11202111461XA (https=)
WO (1) WO2020210916A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2981716C (en) 2015-04-10 2022-04-12 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
CN110291100B (zh) 2016-10-12 2024-06-11 费尔丹生物公司 用于将多肽负荷从细胞外空间递送至靶真核细胞的胞质溶胶和/或细胞核的合理设计的合成肽穿梭剂，其用途、与其相关的方法和试剂盒
CA3040645A1 (en) 2019-04-18 2020-10-18 Feldan Bio Inc. Peptide-based non-proteinaceous cargo delivery
AU2021366976A1 (en) * 2020-10-22 2023-06-08 Feldan Bio Inc. Shuttle agent peptides of minimal length and variants thereof adapted for transduction of cas9-rnp and other nucleoprotein cargos
US20230416334A1 (en) * 2020-11-10 2023-12-28 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Cell-penetrating peptides
CN116997656A (zh) * 2021-02-15 2023-11-03 生物马林药物股份有限公司 富含组氨酸的肽作为用于rAAV和rBV生产的转染试剂的用途
MX2023009816A (es) * 2021-02-24 2024-03-25 Univ Jagiellonski Una jaula de proteínas artificial que comprende una carga de huésped encapsulada en la misma.
JP2024511537A (ja) * 2021-03-29 2024-03-13 フェルダン・バイオ・インコーポレーテッド 細胞内カーゴ送達のための合成ペプチドシャトル媒介物バイオコンジュゲート
WO2023092733A1 (zh) * 2021-11-25 2023-06-01 苏州慧疗生物医药科技有限公司 一种用于有效递送核酸的环状多肽载体及其变化形式
GB202209228D0 (en) 2022-06-23 2022-08-10 Univ Strathclyde Modified amino acids and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016161516A1 (en) * 2015-04-10 2016-10-13 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
WO2017175072A1 (en) * 2016-04-08 2017-10-12 Feldan Bio Inc. Peptide shuttle based gene disruption
WO2018068135A1 (en) * 2016-10-12 2018-04-19 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
FR2849603B1 (fr) 2003-01-07 2006-09-08 Centre Nat Rech Scient Composition pour le transport intracellulaire de macromolecules ou particules biologiques
US7084248B2 (en) 2004-07-14 2006-08-01 Gene Tools, Llc Peptide composition and method for delivering substances into the cytosol of cells
US7579318B2 (en) 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
KR101095841B1 (ko) * 2009-02-19 2011-12-21 주식회사 나이벡 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도
US8895526B2 (en) 2009-03-27 2014-11-25 Cold Spring Harbor Laboratory Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers
EP2470201A4 (en) * 2009-08-28 2013-01-30 Bayer Healthcare Llc COFACTORS ENABLING THE THROMBINIC ACTIVATION OF FACTOR VII AND THEIR USES
US20110165143A1 (en) 2010-01-06 2011-07-07 The Regents Of The University Of Colorado, A Body Corporate Modulation of caspases and therapeutical applications
US8993532B2 (en) 2010-04-23 2015-03-31 Cold Spring Harbor Laboratory Structurally designed shRNAs
WO2013055397A1 (en) 2011-10-14 2013-04-18 Children's Medical Center Corporation Inhibition and enhancement of reprogramming by chromatin modifying enzymes
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
ES2794599T3 (es) 2013-09-10 2020-11-18 Texas A & M Univ Sys Composiciones y métodos para la distribución de moléculas en células vivas
JP7103750B2 (ja) 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
WO2016052442A1 (ja) 2014-09-29 2016-04-07 国立大学法人京都大学 細胞質送達ペプチド
WO2017049407A1 (en) 2015-09-23 2017-03-30 UNIVERSITé LAVAL Modification of the dystrophin gene and uses thereof
EP3184638A1 (en) 2015-12-24 2017-06-28 ETH Zurich Programmable differentiation control network
CA3037635A1 (en) 2016-09-23 2018-03-29 Universite Laval Methods of modifying the dystrophin gene and restoring dystrophin expression and uses thereof
US11629170B2 (en) 2016-10-12 2023-04-18 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
US9982267B2 (en) * 2016-10-12 2018-05-29 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
EP3597223A1 (en) 2018-07-17 2020-01-22 Centre National De La Recherche Scientifique Peptides for use as cell-penetrating peptides
KR20210121092A (ko) 2019-01-29 2021-10-07 유니버시티 오브 워싱턴 유전자 편집 방법
CA3040645A1 (en) 2019-04-18 2020-10-18 Feldan Bio Inc. Peptide-based non-proteinaceous cargo delivery
JP2023545546A (ja) 2020-10-18 2023-10-30 フェルダン・バイオ・インコーポレーテッド 遺伝子発現調節のための非アニオン性ポリヌクレオチド類似体のペプチドに基づく導入
AU2021366976A1 (en) 2020-10-22 2023-06-08 Feldan Bio Inc. Shuttle agent peptides of minimal length and variants thereof adapted for transduction of cas9-rnp and other nucleoprotein cargos
US20220259673A1 (en) 2021-02-09 2022-08-18 Memorial Sloan-Kettering Cancer Center Methods for identifying and treating high-plasticity cell state driving tumor progression in lung cancer
JP2024511537A (ja) 2021-03-29 2024-03-13 フェルダン・バイオ・インコーポレーテッド 細胞内カーゴ送達のための合成ペプチドシャトル媒介物バイオコンジュゲート
US20260033466A1 (en) 2022-08-30 2026-02-05 Feldan Bio Inc. Method and animal model for inducing bcc tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016161516A1 (en) * 2015-04-10 2016-10-13 Feldan Bio Inc. Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
WO2017175072A1 (en) * 2016-04-08 2017-10-12 Feldan Bio Inc. Peptide shuttle based gene disruption
WO2018068135A1 (en) * 2016-10-12 2018-04-19 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same

Also Published As

Publication number Publication date
EP3956348A4 (en) 2023-07-19
CN114008210A (zh) 2022-02-01
CN121652233A (zh) 2026-03-13
CN114008210B (zh) 2025-11-18
SG11202111461XA (en) 2021-11-29
US20220204561A1 (en) 2022-06-30
CA3133525A1 (en) 2020-10-22
IL287271A (en) 2021-12-01
EP3956348A1 (en) 2022-02-23
CA3040645A1 (en) 2020-10-18
WO2020210916A1 (en) 2020-10-22
KR20220031545A (ko) 2022-03-11
AU2020260283A1 (en) 2021-11-11
US12428447B2 (en) 2025-09-30

Similar Documents

Publication Publication Date Title
JP2022529651A (ja) ペプチドに基づく非タンパク質カーゴ送達
JP2022529651A5 (https=)
US12060387B2 (en) Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
JP7177047B2 (ja) ポリペプチドカーゴを標的真核細胞の細胞外間隙からサイトゾルおよび／または核に送達するための合理的に設計された合成ペプチドシャトル剤、その使用、それに関連する方法およびキット
Ajish et al. A novel hybrid peptide composed of LfcinB6 and KR-12-a4 with enhanced antimicrobial, anti-inflammatory and anti-biofilm activities
Orange et al. Cell penetrating peptide inhibitors of nuclear factor-kappa B
US20200270307A1 (en) Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
KR20230088828A (ko) Cas9-rnp 및 기타 핵단백질 카고의 형질도입을 위해 적합화된 최소 길이의 셔틀제 펩타이드 및 그의 변이체
Di Stasi et al. The proline-rich antimicrobial peptide B7-005: low bacterial resistance, safe for human cells and effective in zebrafish embryo bacteraemia model
KR20230086784A (ko) 유전자 발현 변조를 위한 비음이온성 폴리뉴클레오타이드 유사체의 펩타이드 기반 형질도입
Li et al. Membrane-active all-hydrocarbon-stapled α-helical amphiphilic Tat peptides: broad-spectrum antibacterial activity and low incidence of drug resistance
Gül et al. Hybridization of honeybee and frog peptides: Antimicrobial peptides composed of apidaecins and temporins with enhanced activity and production of their electrospun nanofibers
Khamis The effect of isothiocyanates on heat shock protein, heme oxygenase-1 and α-tubulin levels and localization in Xenopus A6 kidney cells
US20120289472A1 (en) Molecules capable of inducing cell death by targeting the mitochondria and applications thereof
Orangea et al. Department of Pediatrics, University of Pennsylvania School of Medicine, The Children s Hospital of Philadelphia 3615 Civic Center Blvd., ARC 1016H, Philadelphia, PA 19104 (USA) b Department of Animal Biology and The Mari Lowe Center for Comparative Oncology, University of Pennsylvania School of Veterinary Medicine, 3800 Spruce Street (OVH 200E), Philadelphia, PA 19104 (USA)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251226